Spike mRNA V2 (Cap1, m1Ψ)

Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence.

价格	￥1500
产品编号	RP-A00065-0.2
规格	0.2 mg 1 mg 大单询价
数量

产品属性质控参数应用指导图例

Description

Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence.

This mRNA features:
- A Cap 1 structure with high capping efficiency
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response
- GenScript’s patented UTR to enhance translation
- A 100A poly(A) tail to mimic natural mature mRNA
- Engineered with optimized linearization site for improved expression.

产品属性

Form	Liquid
Concentration	1mg/mL
Full mRNA length	4090 nt
Full mRNA Molecular Weight	1.32×10^6 Da
Storage buffer	1mM Sodium citrate, pH 6.5
Storage condition	Store at -20°C for short term (<3 months), store at -80°C for long term.

质控参数

Appearance	Clear and free of foreign particles
RNA Length	Expected size band detected
RNA Content	Target ± 5%
Integrity	≥ 75%
OD260/OD280	1.70 ~ 2.30
Capping Efficiency	≥ 90%
Endotoxin	< 10 EU/mg
pH	Target ± 0.5

应用指导

Transfect cells with 2.5μg of mRNA per well (6-well plate) with Lipofectamine™ MessengerMAX™ (or equivalent). 24-48 hours after transfection, detect the expression of Spike protein using flow cytometry analysis with primary antibody against Spike and fluorescent secondary antibody.

图例

Expression of SARS-CoV-2 spike mRNA in A549 cells. »

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.